WITH AN UNRESTRICTED GRANT BY





**INTERNAZIONALE** MENARINI



the cure is with



**KRAKOW** POLAND MAY 3rd - 4th

# **CARDIO-ONCOLOGY**

#### ORGANIZED BY:

DEPARTMENT OF HEMATOLOGY, JAGIELLONIAN UNIVERSITY. **KRAKOW (POLAND)** 

DEPARTMENT OF MEDICINE UNIT OF DRUG SCIENCES AND CLINICAL PHARMACOLOGY CAMPUS BIO-MEDICO UNIVERSITY OF ROME (ITALY)

ABRAMSON CANCER CENTER, PERELMAN SCHOOL OF MEDICINE AT THE UNIVERSITY OF PENNSYLVANIA. PHILADELPHIA, PENNSYLVANIA (US)

UNDER THE **CO-AUSPICES OF:** 



**Oncology Network** 

POLISH NATIONAL ONCOLOGY NETWORK POLISH SOCIETY OF ONCOLOGY



#### Dear Colleagues,

It is my great pleasure to introduce you to the Second International Colloquium on Cardio-Oncology, Krakow, May 3<sup>rd</sup> - 4<sup>th</sup>, 2018.

Cardio-Oncology is a rapidly expanding discipline that focuses on the cardiovascular performance of patients treated with anticancer drugs. It was born to oncologists and cardiologists but quickly involved hematologists, pediatricians and gerontologists, not to mention epidemiologists and preclinical scientists.

There are different approaches one may adopt in addressing cardiooncology. Some believe that cardio-oncology should be a meticulous deciphering and listing of cardiovascular toxicities induced by anticancer drugs. This is in the focus by definition but introduces potential biases that eventually lead doctors to question benefit from some antitumor drugs. Other believe that cardio-oncology should always be guided by a thoughtful analysis of risk:benefit ratio, such that patients eventually receive optimal life-saving treatments while also receiving an adequate cardiovascular surveillance or prophylaxis. We definitely like this second approach better and that is why we invite you to attend a "Colloquium" that is conceived to be an interactive think tank. The Program is self explanatory and goes in that direction.

This Colloquium follows on the International Workshop on Anthracycline Cardiotoxicity that was held in Como back in 2006, and the First International Colloquium on Cardio-Oncology that was held in Rome, 2014. All such events were made possible by the generosity and foresight of Menarini Foundation, which I thankfully acknowledge.

I hope to see you in the historical venue of Krakow for a stimulating and enjoyable colloquium.

President of the Meeting

Giorio Mirest.

Prof. Giorgio Minotti

### SECOND INTERNATIONAL COLLOQUIUM ON CARDIO-ONCOLOGY

KRAKOW (POLAND), MAY 3RD - 4TH , 2018



DEPARTMENT OF MEDICINE UNIT OF DRUG SCIENCES

AND CLINICAL PHARMACOLOGY CAMPUS

**BIO-MEDICO UNIVERSITY OF ROME (ITALY)** 

#### **ORGANIZED BY:**



DEPARTMENT OF HEMATOLOGY, JAGIELLONIAN UNIVERSITY, KRAKOW (POLAND)



Abramson Cancer Center Penn Medicine Philadelphia (Us)

### UNDER THE CO-AUSPICES OF:



POLISH NATIONAL ONCOLOGY NETWORK POLISH SOCIETY OF ONCOLOGY

### CO-PRESIDENTS OF THE MEETING

Giorgio Minotti Campus Bio-Medico University of Rome, Rome, (Italy)

#### Joseph R. Carver

Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania (US)

#### Wojciech Jurczak

Department of Hematology, Jagiellonian University, Krakow (Poland)

### POLISH ONCOLOGY AND NETWORK LEADERS

#### Adam Maciejczyk

President of the Polish National Oncology Network President-Elect of the Polish Society of Oncology

Stanislaw Góźdż Vice President of the Polish National Oncology Network

SCIENTIFIC SECRETARIAT Emanuela Salvatorelli Pierantonio Menna

#### WITH AN UNRESTRICTED GRANT BY

Fondazione Internazionale Menarini

Centro Direzionale Milanofiori 20089 Rozzano (Milan, Italy) Edificio L – Strada 6 Phone: +39 02 55308110 Fax: +39 02 55305739

E-mail: milan@fondazione-menarini.it Website:\\www.fondazione-menarini.it

### PROFESSIONAL CONGRESS ORGANIZER

### Congress Lab Srl

Bastioni di Porta Volta, 10 20121 Milano (Italy) Phone: +39 02 81838672 Cell: +39 3357974061 Fax: +39 02 87181580 E-mail: fondazione@congresslab.it www.congresslab.it

#### Referee:

Stefania Villanacci stefania.villanacci@congresslab.it

FINAL PROGRAMME CONGRESS VENUE: COLLEGIUM NOVUM – JAGIELLONIAN UNIVERSITY

	Thursday, May 3 <sup>rd</sup> 2018 - Morning
	OPENING CONGRESS
•••••	
08.00 a.m. 08.30 a.m.	Arrival and registration of the participants at reception
08.30 a.m. 08.45 a.m.	Foreword <b>G. Minotti</b> (Rome,IT)
	Thursday, May 3 <sup>rd</sup> 2018 - Morning
Se	
of o	ession I – Mechanisms and clinical course cardiovascular toxicity of cancer treatment
	ession I – Mechanisms and clinical course cardiovascular toxicity of cancer treatment
of o	ession I – Mechanisms and clinical course
of ( Oncology	ession I – Mechanisms and clinical course cardiovascular toxicity of cancer treatment G. Minotti (Rome, IT)
of c Oncology Chairpersons:	ession I – Mechanisms and clinical course cardiovascular toxicity of cancer treatment G. Minotti (Rome, IT) M. Długosz-Danecka (Krakow, PL) E. T. H. Yeh (Columbia, MO, US)
of c Oncology Chairpersons: 08.45 a.m.	<ul> <li>G. Minotti (Rome, IT)</li> <li>M. Długosz-Danecka (Krakow, PL)</li> <li>E. T. H. Yeh (Columbia, MO, US)</li> <li>Anthracyclines and nonanthracycline chemotherapeutics</li> <li>M. S. Ewer (Houston, TX, US)</li> </ul>
of a Oncology Chairpersons: 08.45 a.m. 09.15 a.m.	<ul> <li>G. Minotti (Rome, IT) M. Długosz-Danecka (Krakow, PL)</li> <li>E. T. H. Yeh (Columbia, MO, US) Anthracyclines and nonanthracycline chemotherapeutics</li> <li>M. S. Ewer (Houston, TX, US) Anti HER2 drugs</li> <li>J. Moslehi (Nashville, TN, US)</li> </ul>
of a Oncology Chairpersons: 08.45 a.m. 09.15 a.m. 09.45 a.m.	<ul> <li>G. Minotti (Rome, IT)</li> <li>M. Długosz-Danecka (Krakow, PL)</li> <li>E. T. H. Yeh (Columbia, MO, US)</li> <li>Anthracyclines and nonanthracycline chemotherapeutics</li> <li>M. S. Ewer (Houston, TX, US)</li> <li>Anti HER2 drugs</li> <li>J. Moslehi (Nashville, TN, US)</li> <li>Angiogenesis inhibitors</li> <li>Dialogue:</li> <li>J. Moslehi (Nashville, TN, US), M. S. Ewer (Houston, TX, US)</li> </ul>

### Thursday, May 3rd 2018 - Morning

## Session II – Mechanisms and clinical course of cardiovascular toxicity of cancer treatment

### Hematology

Chairpersons:	M. Breccia (Rome, IT) W. Jurczak (Krakow, PL)
11.15 a.m.	M. Breccia (Rome, IT) BCR/ABL1 kinase inhibitors
11.45 a.m.	<b>J. R. Carver</b> (Philadelphia, PA, US) Myeloma drugs
12.15 p.m.	<b>S. Szmit</b> (Warsaw, PL) Emerging paradigms in cardio-oncology: thrombosis and thromboembolism
12.45 p.m.	<b>G. Minotti</b> (Rome, IT) Cautions in brief: good drugs, wrong dosages
01.00 p.m.	Lunch

### Thursday, May 3rd 2018 - Afternoon

### Session III – Cardio-Oncological management of patients

Chairpersons:	<b>A. Torbicki</b> (Warsaw, PL) <b>B. K. Khandheria</b> (Milwaukee, WI, US)
02.00 p.m.	<b>D. M. Cardinale</b> (Milan, IT) Tuning cardio-oncological management to a continuum of early and late events
02.30 p.m.	<b>A. Barac</b> (Washington, DC, US) Imaging: the essential and the superfluous
03.00 p.m.	<b>D. J. Lenihan</b> (St. Louis, MO, US) Primary and secondary prevention of cardiac and vascular toxicity
03.30 p.m.	Coffee break

### Thursday, May 3rd 2018 - Afternoon Session IV – Treatment specific toxicities R. M. Steingart (New York, NY, US) Chairpersons: W. Jurczak (Krakow, PL) C. J. Plummer (London, UK) 04.00 p.m. Cardiovascular risk from hormonal agents J. Plastaras (Philadelphia, PA, US) 04.30 p.m. Cardiac complications of radiation therapy: still a problem? Dialogue: Z. lakobishvili (Petah Tikva, IL), 05.00 p.m. D. J. Lenihan (St. Louis, MO, US), A. Lyon (London, UK) Challenging cases: from QTc prolongation to ibrutinib and atrial fibrillation B. K. Khandheria (Milwaukee, WI, US), J. R. Carver (Philadelphia, PA, US) 05.30 p.m. What did we learn today? End of the day 06.00 p.m. Welcome cocktail

### Friday, May 4th 2018 - Morning

.....

### Session V – Cardio-Oncology in clinical studies and real life

Chairpersons:	<b>T. López-Fernández</b> (Madrid, ES) <b>G. Opolski</b> (Warsaw, PL)
08.30 a.m.	<b>S. Dent</b> (Ottawa, CA) Cardio-Oncology networks for patients
09.00 a.m.	<b>T. Suter</b> (Bern, CH) Strengths and weaknesses of cardiac surveillance in clinical trials
09.30 a.m.	<b>G. Minotti</b> (Rome, IT) Clinical studies with a real life approach: an Italian experience
10.00 a.m.	Discussion
10.30 a.m.	Coffee break

### Friday, May 4th 2018 - Morning

### **Session VI – Cancer survivors**

С	chairpersons:	<b>A. Lyon</b> (London, UK) <b>S. Armenian</b> (Duarte, CA, US)
1	1.00 a.m.	E. Howard (Detroit, MI, US) My life as a cancer survivor
1	1.10 a.m.	<b>R. M. Steingart</b> (New York, NY, US) Follow up of adult cancer survivors: how and how often
1	1.40 a.m.	<b>G. Armstrong</b> (Memphis, TN, US) Chronic health conditions in childhood cancer survivors
1:	2.10 p.m.	<b>F. Lo Coco</b> (Rome, IT) Emerging paradigms in cancer survivorship: what do we know about early and late effects of new cancer therapies?
1:	2.40 p.m.	Discussion
0	1.00 p.m.	Lunch

Friday, N	May 4 <sup>th</sup>	2018 -	Afternoon
-----------	---------------------	--------	-----------

### Session VII – Helping the cardio-oncologist: From real life to guidelines

Chairpersons:	<b>J. R. Carver</b> (Philadelphia, PA, US) <b>A. Gennari</b> (Novara, IT)
02.30 p.m.	<b>S. Armenian</b> (Duarte, CA, US) The ASCO guideline and the ESC position paper
03.00 p.m.	<b>M. S. Ewer</b> (Houston, TX, US), <b>W. Jurczak</b> (Krakow, PL) Would guidelines help in real life?
03.30 p.m.	<ul> <li>G. Minotti (Rome, IT), J. R. Carver (Philadelphia, PA, US),</li> <li>A. Tito Fojo (New York, NY)</li> <li>Take home messages and preparing for Conference Report</li> </ul>
04.00 p.m.	<b>G. Minotti</b> (Rome, IT) Concluding remarks

### **GENERAL INFORMATION**

### **Meeting venue**

The venue for the Meeting will be: "Collegium Novum – Jagiellonian University", Krakow (Poland) Gołębia 24, 31-007 Kraków (Poland)

#### Secretariat during the Meeting

The Secretariat will be open at the following times: Thursday, May 3<sup>rd</sup> 2018 from 08.00 a.m. to 07.00 p.m. Friday, May 4<sup>th</sup> 2018, from 08.00 a.m. to 04.00 p.m.

### **Official language**

The official language of the Meeting will be English. Simultaneous translation will be provided from English to Polish.

#### **Continuing Medical Education (CME)**

Congress Lab Srl is a CME provider – identification code no. 2005 – and has accredited this event for Physicians for the following disciplines: Cardiology, Oncology, Hematology, Radiotherapy, Pediatrics, Genetics, Epidemiology, Geriatrics, Internal medicine, Pharmacology. Please be aware that for the acquisition of the credits is mandatory to have attended the 100% of the whole duration of the congress.

#### Registration

The Meeting is free to attend. For any question and support please contact the Professional Congress Organization (Congress Lab Srl: Phone 1: +39 02 81838672 - Cell: +39 335 7974061 Fax: +39 02 87181580 - E-mail: fondazione@congresslab.it)

### **Technical facilities**

Facilities will be available for computer presentations and overhead projections. A business center with PC (Powerpoint for Windows) will be available for check and preview of presentations. It is essential that speakers take their presentation to the business center at least one hour before the session starts.

The center will be open at the following times: Thursday, May 3<sup>rd</sup> 2018, from 08.00 a.m. to 07.00 p.m. Friday. May 4<sup>th</sup> 2018, from 08.00 a.m. to 04.00 p.m.

#### Lunches and coffee breaks

Lunches and coffee breaks will be served in the Meeting area

### **FACULTY LIST**

Saro Armenian Center for Survivorship and Outcomes, Hematologic Malignancies and Stem Cell Transplantation Institute (Duarte, CA, US) **Gregory Armstrong** Department of Epidemiology and Cancer Control St. Jude Children's Research Hospital (Memphis, TN, US) Ana Barac Medstar Heart and Vascular Institute (Washington, DC, US) Massimo Breccia Sapienza University of Rome (Rome, IT) **Daniela Maria Cardinale** European Institute of Oncology (Milan, IT) Joseph R. Carver University of Pennsylvania Cancer Center (Philadelphia, PA, US) Susan Dent University of Ottawa (Ottawa, CA) Monika Długosz-Danecka Jagiellonian University (Krakow, PL) Michael S. Ewer The University of Texas M. D. Anderson Cancer Center (Houston, TX, US) Alessandra Gennari **Oncology University of Piemonte Orientale** (Novara, IT) **Emily Howard** (Detroit, MI, US) Zaza lakobishvili Holon Medical Center Clalit Health Israel Heart Society (Petah Tikva, IL) Wojciech Jurczak Haematology UJCM (Krakow, PL) **Bijoy K. Khandheria** Karen Yontz Center of Cardio oncology Aurora Health Care (Milwaukee, WI, US) Daniel J. Lenihan Cardio-Oncology Center of Excellence Advanced Heart Failure Clinical Research Cardiovascular **Division Washington University** (St. Louis, MO, US) Francesco Lo Coco University Tor Vergata

(Rome, IT)

Teresa López-Fernández La Paz University Hospital (Madrid, ES) Alexander Lyon the Royal Brompton Hospital (London, UK) **Pierantonio Menna** Campus BIO-MEDICO (Rome, IT) Gioraio Minotti Campus BIO-MEDICO (Rome, IT) Javid Moslehi Medicine Vanderbilt (Nashville, TN, US) Grzegorz Opolski University of Warsaw (Warsaw, PL) John Plastaras University of Pennsylvania (Philadelphia, PA, US) Chris J. Plummer Freeman Hospital (London, UK) Emanuela Salvatorelli Campus BIO-MEDICO (Rome, IT) **Richard M. Steingart** Yale New Haven Hospital (New York, NY, US) Thomas Suter Inselspital, Universitätsspital, Department of Cardiology (Bern, CH) Sebastian Szmit the European Health Centre Otwock (Warsaw, PL) Antonio Tito Fojo Columbia University (New York, NY, US) Adam Torbicki Medical Centre for Postgraduate Education (Warsaw, PL) Yeh Edward T. H. University of Missouri, School of Medicine (Columbia, MO, US)



### Fondazione Internazionale Menarini Symposia n. 385



For more information and for the registration to the Congress, visit the following website:

www.fondazione-menarini.it